Radii Devices secures £494k grant from Innovate UK’s Biomedical Catalyst Fund
Posted on 13th July
Radii Devices – a company which develops technology to improve the fit of external medical devices, and which began its journey on our Health Innovation Programme (HIP) in 2020 has successfully secured investment to fund multi-centre clinical trials.
The innovative technology, which improves the fit of medical devices that connect with the skin such as prosthetics, orthotics, and wheelchairs, will be trialled in several clinics across the UK.
The technology pulls together evidence, based on clinical practice and engineering data using artificial intelligence, and wraps it into software which aims to support the clinician in device design for the best patient outcome.
The upcoming clinical trials will evaluate how well the software works and compare its performance with conventional methods of prosthetic limb fitting, through both quantifiable measures and qualitative experience.
The grant, from Innovate UK’s Biomedical Catalyst fund, provides match funding for Radii’s recent equity investment raise which came from Orthopaedic Research UK and angel investors.
Joshua Steer, founder of Radii Devices said: “We are delighted to receive this funding to support the development and trial of our software to support prosthetic limb fitting. Since the earliest stages of development during our PhD research we’ve always had a clinical trial as a key goal, and we’re delighted that it will now be tested in multiple clinics across the UK.
The West of England AHSN has played a fundamental role in our innovation journey, which started out on its Health Innovation Programme in November 2020. This experience was crucial for the development of our business and the design of our clinical trial. It provided the time and expert feedback to work through the different value propositions for all stakeholders in the NHS and beyond. This has been critical in bringing together our partners for the clinical trial, raising investment, and developing our product for the trial.”